This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
PG&E and the First Climate Change Bankruptcy
Gilson, Stuart C.; Abbott, Sarah L.Case HBS-221057-EFinanceIn early 2020, the California-based utility PG&E filed a second amended plan of reorganization. PG&E had filed for Chapter 11 bankruptcy in the face of more than $30 billion of legal claims brought against it for its alleged role in causing California wildfires. The plan had the support of key creditors and shareholders and a court-appointed committee representing the wildfire victims. However, it faced strong opposition from California's governo...Starting at €8.20
-
E. I. du Pont de Nemours and Company: El split-off de Conoco (A)
Gilson, Stuart C.; Fagan, Perry L.Case HBS-210S21FinanceDespués de tomar el 30% de su filial pública de petróleo y gas de Conoco en la mayor oferta pública inicial doméstica (OPI) en la historia de EE.UU., la gestión de E. I. du Pont de Nemours and Co. (DuPont) está considerando desprenderse de su participación restante en Conoco. Este objetivo se logrará a través de una transacción relativamente poco común llamada corporativa "escisión", bajo la cual se darán los accionistas de DuPont la opción de in...Starting at €8.20
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Case HBS-302S36Knowledge and CommunicationDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Starting at €8.20
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCase HBS-815114-EEntrepreneurshipIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Starting at €8.20
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCase HBS-813091-EEntrepreneurshipSupplement for case 809011Starting at €8.20
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCase HBS-810027-EEntrepreneurshipNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Starting at €8.20
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCase HBS-818068-EStrategyStarting at €8.20
-
Medalogix
Hamermesh, Richard G.; Preble, MatthewCase HBS-815116-EEntrepreneurshipThis case examines an exciting new approach to health care that will help care providers identify when hospice services are the appropriate type of care for patients. The company, Medalogix, already has a product on the market that uses a proprietery algorithm to consider dozens of factors and determine when a patient qualifies for a hospice care eligability review. The product has started to gain traction, and the case explores how Medalogix can...Starting at €8.20
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCase HBS-811089-EEntrepreneurshipIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Starting at €8.20
-
MedImmune Ventures
Hamermesh, Richard G.; Lane, DavidCase HBS-814023-EEntrepreneurshipRon Laufer is the new Senior Managing Director of MedImmune Ventures', the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the incentives he faces as a corporate venture capitalist.Starting at €8.20